CHALLENGES IN UNDERSTANDING THE FUNCTIONAL RELEVANCE OF MICROBIOME SIGNATURES: DRIVER OR PASSENGER
The human body is colonized by a spatially adapted community of microorganisms, reaching highest densities in the large intestine. 1 The composition and function of this ecosystem, represented by the totality of microorganisms (the so-called microbiota) and their collective genomes (the so-called microbiome), including bacteria, viruses, archaea, and eukaryotes, is in a dynamic equilibrium with its human host. 2 Community profiling based on 16S rRNA gene amplicon and metagenomics sequencing indicates that the microbiome can be altered by a variety of environmental and host-related factors, including medication, diet, geography, host physiology, genetics, and age. [3] [4] [5] [6] [7] [8] Increasing evidence suggests that unfavorable shifts in the microbial community structure, function, or both lead to a distortion of microbe-host homeostasis (referred to as dysbiosis) and potentially affects disease susceptibility. Numerous studies identified microbiome signatures with patterns of dysbiosis (eg, reduction of diversity) in patients with a large variety of chronic disorders, including inflammatory bowel diseases (IBD), 9 irritable bowel syndrome, 10 allergy (asthma), 11 rheumatoid arthritis, 12 type 1 diabetes, 13 multiple sclerosis, obesity, 14 type 2 diabetes (T2D), 15 cardiovascular disease, 16 autism spectrum disorder, 17 colorectal cancer, 18 and liver cirrhosis (Fig 1) . 19 An essential question arising from these association studies is whether microbiome alterations are the cause (drivers) or simply the consequence (passengers) of human pathologies. 20 Given the substantial interindividual variation in the microbial community structure and the pleiotropy of confounding factors, microbiome analyses in cross-sectional studies are correlative and require validation in well-controlled replication studies using careful selection of participants based on extensive phenotyping. 21 The implementation of prospective (longitudinal) and treatmentnaive early-onset or birth cohorts might help identify the disease-relevant microbiome signature in a progressive fashion and at very early stages. 22, 23 Unfortunately, disorders with low incidence require prospective cohorts with probably unrealistic size to reach relevant numbers of cases, and thus patient stratification according to drug and other confounding factors might prevent false-positive results.
A recent study from Forslund et al elegantly demonstrated that microbiome changes in patients with T2D using 2 different cohorts of patients from Asia and Europe 24, 25 were drastically confounded by the use of metformin. 26 Interestingly, these findings challenge the role of dysbiosis in the disease etiology of T2D but at the same time encourage the hypothesis that metformin improves insulin sensitivity through microbiome-dependent mechanisms. Although intriguing, the latter suggestion is speculative and requires confirmation. Nevertheless, insulin resistance in patients with T2D was transiently improved after fecal microbiota transplantation (FMT) of lean donor microbiota into obese recipients without affecting their weight. 27 These findings clearly illustrate that stool transplantations have a direct and metforminindependent clinical effect, demonstrating the lack of consolidated knowledge regarding microbiome signatures in the pathogenesis of obesity-associated metabolic disorders. FMT was also effective in patients with Clostridium difficile infections, supporting the concept that complex microbial ecosystems transfer beneficial effects to a recipient host. 28 Unanswered is the question of whether the engraftment of bacterial strains from donor to recipient is a prerequisite for beneficial effects. 29 Interestingly, use of sterile filtered stool liquid was also able to achieve clinical efficacy in the treatment of patients with C difficile, suggesting that secreted meditators from the host or microbiome potentially contribute to FMT responsiveness. 30 In addition to well-controlled intervention studies, enrolling treatment-naive patient populations is another promising strategy to identify clinically relevant microbiome signatures. IBD are chronically relapsing inflammatory disorders of the gastrointestinal tract, with Crohn disease and ulcerative colitis as the main clinical entities. 31 Genome-wide association studies substantiated clinical and animal studies in assigning an essential role of the microbiome for disease cause. 32 In this context Gevers et al 23 confirmed in a pediatric cohort (RISK) of freshly diagnosed patients with Crohn disease that dysbiosis is associated with a loss of species diversity and selective changes in the community structure. Disease-related microbiome signatures were most pronounced in samples obtained from the mucosal tissue and showed only weak association in stool, clearly demonstrating that site-specific sampling is very important to achieve meaningful results. Antibiotic exposure amplified the dysbiotic feature of the microbiome signatures and clearly supports the observation from adult IBD cohorts that medication (eg, anti-TNF or iron replacement therapy) is a major confounder for microbiome analysis. 33, 34 In addition to already established biomarkers, Gevers et al 23 added new taxa associated with increase or reduced abundance in patients with Crohn disease which, need to be replicated in other patient cohorts. However, a follow-up study already made clear that the integration of patient-specific transcriptional profiles and microbiome signatures allow a better stratification of patients with Crohn disease and ulcerative colitis. 35 Loss of species diversity is associated with a variety of human pathologies and therefore might only be the consequence of drastic changes in the environmental milieu. Initially, 2 placebocontrolled FMT trials with patients with ulcerative colitis revealed opposite clinical efficacy, 36, 37 leaving many questions with regard to the route of application, dosing, and donor selection unanswered. However, the recently published multicentered Fecal Microbiota Transplantation for Active Ulcerative Colitis Study demonstrated that a high-dose multidonor infusion of fecal material was efficient in inducing steroid-free clinical remission and steroid-free endoscopic response at week 8, confirming clinical efficacy for microbial therapy in patients with ulcerative colitis. 38 In contrast to acute C difficile infections in which FMT restores a healthy microbial environment and eradicates the infectious agent from the host, the challenge in patients with IBD is to maintain stable remission after initial FMT. Repetitive FMT or the use of synthetic bacterial consortia might be required to achieve longterm changes of a disease-associated microbial ecosystem. Dietary interventions with elemental enteral diets in patients with Crohn disease seem an alternative method for microbiome engineering with potential therapeutic value. 39, 40 Early-life colonization of the digestive tract has a profound effect on development of the immune system, and atopy is one of the most common immune abnormalities associated with increased risk for childhood asthma. 41 A recent study with a birth cohort of 298 infants identified a positive correlation between the presence of a dysbiotic neonatal microbiome and the promotion of IL-4-producing T cells, 11 supporting recent findings that alterations of the microbiome and metabolome at early-life stages (3 months) affect the risk of childhood asthma. 42 The atopyassociated immune imbalance correlated with changes in the relative abundance of bacterial and fungal taxa, such as Bifidobacterium, Akkermansia, Faecalibacterium, and Candida species, adding new suggestions to a long list of bacterial taxa with potentially disease-related effects (Table I) . 10, [12] [13] [14] [15] 18, 19, [23] [24] [25] [26] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] Considering the currently available data, we can only speculate about the prognostic and therapeutic value of microbiome signatures. In addition to replication studies, it seems essential to further characterize the molecular and cellular effectors of the microbiome to address functional heterogeneity at the strain level and to screen for bacteria-related drug application. Hypothesisdriven and evidence-based selection of single bacteria or synthetic consortia of bacteria might provide the next generation of probiotic intervention without risking adverse consequences because of use of undefined bacteria. In recent years, technologies available to interrogate the human microbiome, such as metagenomics, metatranscriptomics, metaproteomics, and metametabolomics, have been developing at a remarkable pace, and as a consequence, protocols require efficient harmonization and standardization at all levels. Analyses of population-based samples should include all possible information related to the methodological process, as well as the host (eg, ethnicity, geographic locations, and dietary habits). 61 It has been proven how sampling procedures and storage can drastically alter the results of microbiome analyses. 62 Furthermore, use of different analytic pipelines leads to the generation of biased data. [63] [64] [65] Culture-independent metagenomic pipelines are able to enumerate all microbial taxa in a given sample and genes correlated with host phenotypes but mostly rely on comparisons to reference genomes from cultivated microbes. In fact, reference genomes can resolve only taxa for which representative sequence information is available, and thus they mirror only a fraction of the microorganisms present in a certain sample. Innovative strategies have been proposed to overcome this limitation, such as the coabundance-based method and the marker gene sequence method. These approaches identify microbial communities in complex samples by resolving metagenomic data into groups of genes based on coabundance (so-called CAGs) 66 or into metagenomic operational taxonomic units linkage groups (mOTULGs) based on species-level taxonomic abundances and phylogenetic marker genes. 67 The next level to further exploit metagenomic information is to predict structures of the microbiota-related secretome based on analysis of biosynthetic gene clusters. The emphasis lies on identification of small molecules that affect the biological activity of the host. 68 A recent example of this strategy is the discovery of gene clusters that encode pyrazinones or dihydropyrazinones with potent protease inhibitory activity capable of targeting host-derived cathepsins. 69 Bile acids are present in the gut lumen in millimolar concentrations and affect a variety of metabolic and inflammatory diseases, as well as cancer. Computational approaches were used to identify biosynthetic genes responsible for bile acid conversion, mounting a pool of bacteria-modified bile acids (up to 1 mmol/L) in the large intestine. 70 Ruminococcus gnavus was identified as a novel inducer of isobile formation, demonstrating the power of this reverse genetic approach to identify functional metabolites and relevant taxa responsible for their production.
First efforts to isolate and characterize the ''unculturable biomass'' of the human and mouse microbiota are underway and most desired, 71 ,72 yet the highest efforts have been made to build bacterial gene catalogues from human, 73 mouse, 74 and pig 75 metagenomic data sets. Limitations to cultivate all gut microbial communities include mutualistic feeding relationships among the bacterial community members, very slow growth rates, strict anaerobiosis, and inadequate cultivation methods. A very recent study demonstrated that these limitations can be overcome and proposed a novel workflow based on spore isolation, which allows culture of a substantial proportion of human gut unculturable bacteria. 71 Establishing a comprehensive repertoire of culturable bacteria representing key functions or species of the microbiome allows analysis of a wide range of physiologic functions and diseases in gnotobiotic model organisms. 72, 76 These aspects are highly pertinent to the selection of bacterial strains for human functional and translational research.
In conclusion, the future workflow of metagenomic analysis certainly goes toward the identification of functional mediators, and in combination with the effort to cultivate novel bacterial strains from the ''unknown biomass,'' the correlation era in microbiome will be overcome.
Gnotobiotic model systems: From single-strain to bacterial consortia to humanization protocols
Gnotobiotic models have been used to reveal causative association between changes in the microbiome in health and disease and to gain functional insights into host-microbe interactions. 77 To address this aspect, a reductionist approach has been adopted to focus the investigation on specific taxa or metabolites of interest, revealing the potential mechanism or mechanisms responsible for the phenomenon observed. One example is the use of IBD-related mouse models monoassociated with a variety of commensal bacteria, including Escherichia coli, Enterococcus faecalis, Bacteroides vulgatus, and Bilophila wadsworthia.
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Isogenic mutant strains lacking bacterial components substantially improved our understanding of the molecular mechanisms of microbe-host interactions in disease initiation or protection. [79] [80] [81] [82] Because the use of single bacteria most likely does not represent the complexity in microbiome-related human diseases, the logical next step is to generate combinations of wellcharacterized and fully sequenced bacterial strains (eg, SIHUMI 83 and Oligo-Mouse-Microbiota
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). These synthetic consortia allow us to establish hypothesis-driven minimal microbiomes, providing a powerful tool to investigate complex mechanisms of host-microbiota and bacterium-bacterium crosstalk under normal and disease-susceptible conditions. In addition, the availability of defined synthetic consortia might also help to standardize the variable phenotypes of disease models observed under the housing conditions in different mouse houses. 84 In addition, gnotobiotic models have been exploited to investigate the disease potential of complex communities. In the context of Crohn disease-related models, functional evidence was provided for the existence of a disease-conditioning ecosystem (microbiome signatures with dysbiotic phenotype) that is capable of initiating and transmitting the disease phenotype into a germ-free host. Most important for the understanding of chronic intestinal inflammation, the complex microbiota triggers disease in the genetically susceptible but not wild-type host, confirming that the aggressive phenotype is transferred through the commensal environment and not through infectious organisms. 85 Similar transfer experiments confirmed a causal relationship for the disease-initiating microbiome in the context of colitis, 86 colitis-associated cancer, 87 type 1 diabetes, 88 multiple sclerosis models, 89 and metabolic diseases. 90, 91 These gnotobiotic studies provide essential proof of concept that noninfectious microbial ecosystems in the gut harbor the capability to induce immune-related and metabolically related pathologies. Nevertheless, microbiota transfer studies in gnotobiotic mouse models (eg, obesity) lack partial reproducibility, [92] [93] [94] [95] suggesting diet-and mouse house-specific microbiota as confounding factors.
Germ-free mouse models are also colonized with human fecal microbiota (so-called humanized mice) to further accelerate translational research. Several studies appear to phenocopy in cancer therapy. Yet the question remains whether inoculating human microbiota into germ-free recipient mice is an adequate tool to study disease mechanisms and clinical phenotypes. It is important to consider that the cross-species exchange of microbiota exerts an intrinsic host specificity, 102 host immune system maturation, 103 host gut selective pressure, 104 and host glycan repertoire. 105, 106 In addition, ecological factors that drive dysbiosis in human patients are no longer present when their microbiota is inoculated into mouse models, 107, 108 suggesting that the mechanistic insight from these translation studies might be limited. An important goal in the next years is to carefully evaluate the pros and cons of humanized murine models to draw adequate conclusions from these novel tools in translational microbiome research.
CONCLUSION
Compelling evidence from human and mouse studies supports the view that the microbiome plays an important role in the pathogenesis of human diseases. However, the multifactorial nature of most of these pathologies and the existence of a variety of confounding factors in human and mouse studies hamper a clear conclusion on how microbiome signatures should be clinically implemented for prognostic and therapeutic purposes. It is still unclear to what extent disease risk is predicable based on characteristic changes in bacterial community structure, function, or both and whether microbiome changes have a causal role in disease onset. The development of standards is essential to ensure reproducibility and comparability between human and mouse studies. The scientific field needs to validate the specificity and selectivity of microbiome signatures in each disease entity, considering different mechanisms in the onset and progression of the various disorders. To reach this goal, research strategies need to go beyond metagenomics sequencing, aiming at identification of functional mediators and, most importantly, addressing mechanistic links between microbiota-derived signals and host sensors, finally leading to evidence-based intervention strategies selectively targeted to specific human diseases (Fig 2) .
